Menopause-linked blood proteins associated with cognitive aging and dementia risk

Researchers have identified a blood-protein pattern associated with menopause that also tracks with cognitive aging and dementia risk in older women. The findings offer a possible route toward studying brain vulnerability during midlife, while leaving unanswered whether measuring or changing those proteins could improve health outcomes.

The study appeared in Nature Medicine on September 22. UC San Francisco highlighted the research on September 24, describing the eventual goal of developing an early-warning blood test. That remains a research ambition: the published associations do not establish a test that can reliably tell an individual woman whether she will develop dementia.

Connecting menopause biology with later-life outcomes

The observational investigation began with 80 women aged 43–58, classified into premenopausal, perimenopausal and postmenopausal groups using standardized reproductive-aging criteria. Researchers identified 16 proteins elevated after menopause, spanning inflammation, neuronal communication, metabolism and Alzheimer’s-related biology.

They then examined an age-matched validation sample of 2,814 women and four separate cohorts totaling 11,925 older women. Higher menopause-related protein scores were associated with less favorable cognitive outcomes and dementia risk. These were comparisons across study populations, rather than decades of follow-up of the original 80 women from menopause into old age.

UCSF’s account emphasizes that the molecular patterns tracked more closely with reproductive hormones than with chronological age. Inflammation-related proteins tended to rise as estradiol fell, while another group associated with Alzheimer’s biology tracked rising follicle-stimulating hormone. These relationships provide hypotheses about biological pathways; they do not show that either hormonal change causes dementia.

Why the distinction matters

Menopause is a normal life transition, not a disease. The National Institute on Aging describes a broad range of experiences, from few symptoms to disrupted sleep, hot flashes, forgetfulness and difficulty concentrating. Those experiences alone do not constitute a dementia diagnosis.

The wider scientific question is how reproductive aging interacts with other changes during midlife. NIA-supported research has examined connections among menopausal symptoms, sleep, cardiovascular health and brain structure. This makes the new protein findings relevant to healthspan research: they may help investigators separate overlapping processes that are difficult to distinguish using age or symptoms alone.

Several limitations constrain that interpretation. The discovery sample was small, with protein and hormone measurements taken at one point in time. Symptoms were self-reported, blood proteins can originate from multiple tissues, and some protein findings did not replicate consistently across measurement platforms. A circulating signal therefore cannot automatically be read as evidence of damage inside the brain.

Treatment and screening remain separate questions

The study does not test whether hormone therapy prevents cognitive decline. A separate systematic review and meta-analysis, available through PubMed, found no significant overall association between menopausal hormone therapy and the risk of mild cognitive impairment or dementia. Its evidence certainty ranged from moderate to very low, and the authors called for stronger long-term studies addressing treatment formulation, timing and other differences.

Together, these findings illustrate why identifying a biological association and demonstrating a useful intervention require different evidence. A marker could help explain disease pathways without being accurate enough for screening, or without identifying a treatment that changes outcomes.

UCSF says a planned Longitudinal Menopause Project will follow women through the transition using repeated blood sampling, brain imaging and cognitive assessments. Tracking changes within the same people should help clarify the sequence of events. For now, the practical contribution is a set of candidate signals for research into women’s brain aging, with clinical usefulness still to be demonstrated.